Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Deals With Respivert And Orexo, J&J's Respiratory Push Gets Going

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J acquired respiratory drug discovery firm Respivert and licensed two respiratory preclinical research programs from Orexo.

You may also be interested in...



Janssen Builds A Pulmonary Pipeline: An Interview With Sue Dillon

Citing high unmet medical need and significant commercial opportunity, Janssen Research & Development has dived into pulmonary therapeutics. TA head of immunology Sue Dillon discusses the rationale, the indications and the therapeutic approaches the company is taking.

Imperial Innovations Raises £140 Million To Invest In University Spin-Outs

The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities

Imperial Innovations Raises £140 Million To Invest In University Spin-Outs

The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel